title: Peptide and protein-based inhibitors of HIV-1 co-receptors.
abstract: Human immunodeficiency virus (HIV) afflicts an estimated 30 million people globally, making it a continuing pandemic. Despite major research efforts, the rate of new infections has remained relatively static over time. This article reviews an emerging strategy for the treatment of HIV, the inhibition of the co-receptors necessary for HIV entry, CCR5 and CXCR4. The aim of this article is to highlight potential therapeutics derived from peptides and proteins that show particular promise in HIV treatment. Molecules that act on CCR5, CXCR4 or on both receptors will be discussed herein.
authors.affiliation: Department of Biomedical Engineering, Case Western Reserve University, Cleveland, OH, USA.
authors.forename: Horst A
authors.initials: HA
authors.lastname: von Recum
authors.forename: Jonathan K
authors.initials: JK
authors.lastname: Pokorski
mesh_terms: D000818:Animals; D065100:CCR5 Receptor Antagonists; D023581:HIV Fusion Inhibitors / Q000627:therapeutic use*; D015658:HIV Infections / Q000188:drug therapy / Q000453:epidemiology; D015497:HIV-1; D006801:Humans; D058873:Pandemics; D010455:Peptides / Q000627:therapeutic use*; D019718:Receptors, CXCR4 / Q000037:antagonists & inhibitors*; D053586:Virus Internalization / Q000187:drug effects
chemical_list: D065100:CCR5 Receptor Antagonists; C527276:CXCR4 protein, human; D023581:HIV Fusion Inhibitors; D010455:Peptides; D019718:Receptors, CXCR4
keywords: CCR5; CXCR4; HIV